Early metabolic markers identify potential targets for the prevention of type 2 diabetes.
Identifieur interne : 000D77 ( PubMed/Checkpoint ); précédent : 000D76; suivant : 000D78Early metabolic markers identify potential targets for the prevention of type 2 diabetes.
Auteurs : Gopal Peddinti [Finlande] ; Jeff Cobb [États-Unis] ; Loic Yengo [France] ; Philippe Froguel [France] ; Jasmina Kravi [Suède] ; Beverley Balkau [France] ; Tiinamaija Tuomi [Finlande] ; Tero Aittokallio [Finlande] ; Leif Groop [Finlande]Source :
- Diabetologia [ 1432-0428 ] ; 2017.
Abstract
The aims of this study were to evaluate systematically the predictive power of comprehensive metabolomics profiles in predicting the future risk of type 2 diabetes, and to identify a panel of the most predictive metabolic markers.
DOI: 10.1007/s00125-017-4325-0
PubMed: 28597074
Affiliations:
- Finlande, France, Suède, États-Unis
- Caroline du Nord, Hauts-de-France, Nord-Pas-de-Calais, Uusimaa
- Helsinki, Lille
- Université d'Helsinki
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:28597074Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Early metabolic markers identify potential targets for the prevention of type 2 diabetes.</title><author><name sortKey="Peddinti, Gopal" sort="Peddinti, Gopal" uniqKey="Peddinti G" first="Gopal" last="Peddinti">Gopal Peddinti</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland. gopal.peddinti@vtt.fi.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Cobb, Jeff" sort="Cobb, Jeff" uniqKey="Cobb J" first="Jeff" last="Cobb">Jeff Cobb</name><affiliation wicri:level="2"><nlm:affiliation>Metabolon Inc., Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Metabolon Inc., Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Yengo, Loic" sort="Yengo, Loic" uniqKey="Yengo L" first="Loic" last="Yengo">Loic Yengo</name><affiliation wicri:level="3"><nlm:affiliation>CNRS UMR8199, Pasteur Institute of Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR8199, Pasteur Institute of Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Froguel, Philippe" sort="Froguel, Philippe" uniqKey="Froguel P" first="Philippe" last="Froguel">Philippe Froguel</name><affiliation wicri:level="3"><nlm:affiliation>CNRS UMR8199, Pasteur Institute of Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR8199, Pasteur Institute of Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Kravi, Jasmina" sort="Kravi, Jasmina" uniqKey="Kravi J" first="Jasmina" last="Kravi">Jasmina Kravi</name><affiliation wicri:level="1"><nlm:affiliation>Lund University Diabetes Center, Lund, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Lund University Diabetes Center, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Balkau, Beverley" sort="Balkau, Beverley" uniqKey="Balkau B" first="Beverley" last="Balkau">Beverley Balkau</name><affiliation wicri:level="1"><nlm:affiliation>CESP, Faculty of Medicine - University Paris-South; Faculty of Medicine - University Versailles-St Quentin; Inserm U1018, University Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CESP, Faculty of Medicine - University Paris-South; Faculty of Medicine - University Versailles-St Quentin; Inserm U1018, University Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Tuomi, Tiinamaija" sort="Tuomi, Tiinamaija" uniqKey="Tuomi T" first="Tiinamaija" last="Tuomi">Tiinamaija Tuomi</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Aittokallio, Tero" sort="Aittokallio, Tero" uniqKey="Aittokallio T" first="Tero" last="Aittokallio">Tero Aittokallio</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Groop, Leif" sort="Groop, Leif" uniqKey="Groop L" first="Leif" last="Groop">Leif Groop</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28597074</idno><idno type="pmid">28597074</idno><idno type="doi">10.1007/s00125-017-4325-0</idno><idno type="wicri:Area/PubMed/Corpus">000B13</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B13</idno><idno type="wicri:Area/PubMed/Curation">000B10</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B10</idno><idno type="wicri:Area/PubMed/Checkpoint">000B10</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B10</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Early metabolic markers identify potential targets for the prevention of type 2 diabetes.</title><author><name sortKey="Peddinti, Gopal" sort="Peddinti, Gopal" uniqKey="Peddinti G" first="Gopal" last="Peddinti">Gopal Peddinti</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland. gopal.peddinti@vtt.fi.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Cobb, Jeff" sort="Cobb, Jeff" uniqKey="Cobb J" first="Jeff" last="Cobb">Jeff Cobb</name><affiliation wicri:level="2"><nlm:affiliation>Metabolon Inc., Durham, NC, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Metabolon Inc., Durham, NC</wicri:regionArea><placeName><region type="state">Caroline du Nord</region></placeName></affiliation></author><author><name sortKey="Yengo, Loic" sort="Yengo, Loic" uniqKey="Yengo L" first="Loic" last="Yengo">Loic Yengo</name><affiliation wicri:level="3"><nlm:affiliation>CNRS UMR8199, Pasteur Institute of Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR8199, Pasteur Institute of Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Froguel, Philippe" sort="Froguel, Philippe" uniqKey="Froguel P" first="Philippe" last="Froguel">Philippe Froguel</name><affiliation wicri:level="3"><nlm:affiliation>CNRS UMR8199, Pasteur Institute of Lille, Lille, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CNRS UMR8199, Pasteur Institute of Lille, Lille</wicri:regionArea><placeName><region type="region">Hauts-de-France</region><region type="old region">Nord-Pas-de-Calais</region><settlement type="city">Lille</settlement></placeName></affiliation></author><author><name sortKey="Kravi, Jasmina" sort="Kravi, Jasmina" uniqKey="Kravi J" first="Jasmina" last="Kravi">Jasmina Kravi</name><affiliation wicri:level="1"><nlm:affiliation>Lund University Diabetes Center, Lund, Sweden.</nlm:affiliation><country xml:lang="fr">Suède</country><wicri:regionArea>Lund University Diabetes Center, Lund</wicri:regionArea><wicri:noRegion>Lund</wicri:noRegion></affiliation></author><author><name sortKey="Balkau, Beverley" sort="Balkau, Beverley" uniqKey="Balkau B" first="Beverley" last="Balkau">Beverley Balkau</name><affiliation wicri:level="1"><nlm:affiliation>CESP, Faculty of Medicine - University Paris-South; Faculty of Medicine - University Versailles-St Quentin; Inserm U1018, University Paris-Saclay, Villejuif, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>CESP, Faculty of Medicine - University Paris-South; Faculty of Medicine - University Versailles-St Quentin; Inserm U1018, University Paris-Saclay, Villejuif</wicri:regionArea><wicri:noRegion>Villejuif</wicri:noRegion><wicri:noRegion>Villejuif</wicri:noRegion></affiliation></author><author><name sortKey="Tuomi, Tiinamaija" sort="Tuomi, Tiinamaija" uniqKey="Tuomi T" first="Tiinamaija" last="Tuomi">Tiinamaija Tuomi</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Aittokallio, Tero" sort="Aittokallio, Tero" uniqKey="Aittokallio T" first="Tero" last="Aittokallio">Tero Aittokallio</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author><author><name sortKey="Groop, Leif" sort="Groop, Leif" uniqKey="Groop L" first="Leif" last="Groop">Leif Groop</name><affiliation wicri:level="4"><nlm:affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</nlm:affiliation><country xml:lang="fr">Finlande</country><wicri:regionArea>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki</wicri:regionArea><orgName type="university">Université d'Helsinki</orgName><placeName><settlement type="city">Helsinki</settlement><region type="région" nuts="2">Uusimaa</region></placeName></affiliation></author></analytic><series><title level="j">Diabetologia</title><idno type="eISSN">1432-0428</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The aims of this study were to evaluate systematically the predictive power of comprehensive metabolomics profiles in predicting the future risk of type 2 diabetes, and to identify a panel of the most predictive metabolic markers.</div></front></TEI><pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">28597074</PMID><DateCreated><Year>2017</Year><Month>06</Month><Day>09</Day></DateCreated><DateRevised><Year>2017</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-0428</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2017</Year><Month>Jun</Month><Day>08</Day></PubDate></JournalIssue><Title>Diabetologia</Title><ISOAbbreviation>Diabetologia</ISOAbbreviation></Journal><ArticleTitle>Early metabolic markers identify potential targets for the prevention of type 2 diabetes.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00125-017-4325-0</ELocationID><Abstract><AbstractText Label="AIMS/HYPOTHESIS" NlmCategory="OBJECTIVE">The aims of this study were to evaluate systematically the predictive power of comprehensive metabolomics profiles in predicting the future risk of type 2 diabetes, and to identify a panel of the most predictive metabolic markers.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We applied an unbiased systems medicine approach to mine metabolite combinations that provide added value in predicting the future incidence of type 2 diabetes beyond known risk factors. We performed mass spectrometry-based targeted, as well as global untargeted, metabolomics, measuring a total of 568 metabolites, in a Finnish cohort of 543 non-diabetic individuals from the Botnia Prospective Study, which included 146 individuals who progressed to type 2 diabetes by the end of a 10 year follow-up period. Multivariate logistic regression was used to assess statistical associations, and regularised least-squares modelling was used to perform machine learning-based risk classification and marker selection. The predictive performance of the machine learning models and marker panels was evaluated using repeated nested cross-validation, and replicated in an independent French cohort of 1044 individuals including 231 participants who progressed to type 2 diabetes during a 9 year follow-up period in the DESIR (Data from an Epidemiological Study on the Insulin Resistance Syndrome) study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Nine metabolites were negatively associated (potentially protective) and 25 were positively associated with progression to type 2 diabetes. Machine learning models based on the entire metabolome predicted progression to type 2 diabetes (area under the receiver operating characteristic curve, AUC = 0.77) significantly better than the reference model based on clinical risk factors alone (AUC = 0.68; DeLong's p = 0.0009). The panel of metabolic markers selected by the machine learning-based feature selection also significantly improved the predictive performance over the reference model (AUC = 0.78; p = 0.00019; integrated discrimination improvement, IDI = 66.7%). This approach identified novel predictive biomarkers, such as α-tocopherol, bradykinin hydroxyproline, X-12063 and X-13435, which showed added value in predicting progression to type 2 diabetes when combined with known biomarkers such as glucose, mannose and α-hydroxybutyrate and routinely used clinical risk factors.</AbstractText><AbstractText Label="CONCLUSIONS/INTERPRETATION" NlmCategory="CONCLUSIONS">This study provides a panel of novel metabolic markers for future efforts aimed at the prevention of type 2 diabetes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peddinti</LastName><ForeName>Gopal</ForeName><Initials>G</Initials><Identifier Source="ORCID">http://orcid.org/0000-0002-8767-968X</Identifier><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland. gopal.peddinti@vtt.fi.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>, Tietotie 2, P. O. Box 1000, FIN-02044 VTT, Espoo, Finland. gopal.peddinti@vtt.fi.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cobb</LastName><ForeName>Jeff</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Metabolon Inc., Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yengo</LastName><ForeName>Loic</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>CNRS UMR8199, Pasteur Institute of Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Genomic Institute for Diabetes (EGID), FR-3508, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Bioscience, The University of Queensland, Brisbane, QLD, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Froguel</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CNRS UMR8199, Pasteur Institute of Lille, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>European Genomic Institute for Diabetes (EGID), FR-3508, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lille University, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genomics of Common Disease, School of Public Health, Imperial College London, Hammersmith Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kravić</LastName><ForeName>Jasmina</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Lund University Diabetes Center, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balkau</LastName><ForeName>Beverley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CESP, Faculty of Medicine - University Paris-South; Faculty of Medicine - University Versailles-St Quentin; Inserm U1018, University Paris-Saclay, Villejuif, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tuomi</LastName><ForeName>Tiinamaija</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Endocrinology, Abdominal Centre, Helsinki University Central Hospital, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Folkhalsan Research Center and Research Programs Unit, Diabetes and Obesity, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aittokallio</LastName><ForeName>Tero</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Mathematics and Statistics, University of Turku, Turku, Finland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Groop</LastName><ForeName>Leif</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute for Molecular Medicine Finland (FIMM), Nordic EMBL Partnership for Molecular Medicine, University of Helsinki, Helsinki, Finland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Lund University Diabetes Center, Lund, Sweden.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>06</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Diabetologia</MedlineTA><NlmUniqueID>0006777</NlmUniqueID><ISSNLinking>0012-186X</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Clin Chem. 2015 Mar;61(3):487-97</RefSource><PMID Version="1">25524438</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2005 Jan;54(1):166-74</RefSource><PMID Version="1">15616025</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Metabolism. 2000 Jul;49(7):920-30</RefSource><PMID Version="1">10910005</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Drug Discov. 2016 Jul;15(7):473-84</RefSource><PMID Version="1">26965202</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2013 May;62(5):1730-7</RefSource><PMID Version="1">23160532</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>World J Diabetes. 2014 Oct 15;5(5):659-65</RefSource><PMID Version="1">25317243</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2009 Nov;58(11):2429-43</RefSource><PMID Version="1">19875619</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2016 Apr 9;387(10027):1513-30</RefSource><PMID Version="1">27061677</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Med. 2010 Apr;42(3):178-86</RefSource><PMID Version="1">20350251</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010 Nov 11;5(11):e13953</RefSource><PMID Version="1">21085649</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Heart Dis. 2001 Sep-Oct;3(5):333-9</RefSource><PMID Version="1">11975815</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Genet. 2014 Mar 13;10(3):e1004212</RefSource><PMID Version="1">24625756</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2013 Jul;62(7):2266-77</RefSource><PMID Version="1">23474485</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2014 Aug;63(8):2613-6</RefSource><PMID Version="1">25060893</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Bioinformatics. 2005 Oct 15;21(20):3940-1</RefSource><PMID Version="1">16096348</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Apr 16;9(4):e95008</RefSource><PMID Version="1">24740143</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Stat Med. 2008 Jan 30;27(2):157-72; discussion 207-12</RefSource><PMID Version="1">17569110</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Cheminform. 2014 Mar 29;6(1):10</RefSource><PMID Version="1">24678909</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2013 Feb;62(2):639-48</RefSource><PMID Version="1">23043162</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Metab. 2016 Aug 23;5(10 ):918-25</RefSource><PMID Version="1">27689004</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes Care. 2016 May;39(5):833-46</RefSource><PMID Version="1">27208380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Bioinformatics. 2011 Mar 17;12:77</RefSource><PMID Version="1">21414208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Biometrics. 1988 Sep;44(3):837-45</RefSource><PMID Version="1">3203132</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetologia. 2008 Jan;51(1):47-53</RefSource><PMID Version="1">17994292</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2014 Aug 06;9(8):e103981</RefSource><PMID Version="1">25100328</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2011 Apr;17(4):448-53</RefSource><PMID Version="1">21423183</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2010 May 28;5(5):e10883</RefSource><PMID Version="1">20526369</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anal Chem. 2009 Aug 15;81(16):6656-67</RefSource><PMID Version="1">19624122</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Diabetes Res. 2016;2016:3898502</RefSource><PMID Version="1">26636104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nutrition. 2015 Jan;31(1):119-26</RefSource><PMID Version="1">25466655</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell Metab. 2016 Jul 12;24(1):172-84</RefSource><PMID Version="1">27345421</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2014 Aug;63(8):2845-53</RefSource><PMID Version="1">24677717</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Trends Biotechnol. 2004 May;22(5):245-52</RefSource><PMID Version="1">15109811</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Syst Biol. 2012;8:615</RefSource><PMID Version="1">23010998</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Algorithms Mol Biol. 2012 May 02;7(1):11</RefSource><PMID Version="1">22551170</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013 Nov 12;8(11):e80348</RefSource><PMID Version="1">24265812</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Acta Diabetol. 2012 Jun;49(3):167-83</RefSource><PMID Version="1">22218826</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Diabetes. 2013 Dec;62(12):4270-6</RefSource><PMID Version="1">23884885</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann N Y Acad Sci. 2010 Aug;1203:101-6</RefSource><PMID Version="1">20716290</PMID></CommentsCorrections></CommentsCorrectionsList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Early prediction</Keyword><Keyword MajorTopicYN="N">Kallikrein–kinin system</Keyword><Keyword MajorTopicYN="N">Machine learning</Keyword><Keyword MajorTopicYN="N">Metabolomics</Keyword><Keyword MajorTopicYN="N">Multivariate models</Keyword><Keyword MajorTopicYN="N">Prevention</Keyword><Keyword MajorTopicYN="N">Risk classification</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>02</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>05</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>6</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28597074</ArticleId><ArticleId IdType="doi">10.1007/s00125-017-4325-0</ArticleId><ArticleId IdType="pii">10.1007/s00125-017-4325-0</ArticleId><ArticleId IdType="pmc">PMC5552834</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Finlande</li><li>France</li><li>Suède</li><li>États-Unis</li></country><region><li>Caroline du Nord</li><li>Hauts-de-France</li><li>Nord-Pas-de-Calais</li><li>Uusimaa</li></region><settlement><li>Helsinki</li><li>Lille</li></settlement><orgName><li>Université d'Helsinki</li></orgName></list><tree><country name="Finlande"><region name="Uusimaa"><name sortKey="Peddinti, Gopal" sort="Peddinti, Gopal" uniqKey="Peddinti G" first="Gopal" last="Peddinti">Gopal Peddinti</name></region><name sortKey="Aittokallio, Tero" sort="Aittokallio, Tero" uniqKey="Aittokallio T" first="Tero" last="Aittokallio">Tero Aittokallio</name><name sortKey="Groop, Leif" sort="Groop, Leif" uniqKey="Groop L" first="Leif" last="Groop">Leif Groop</name><name sortKey="Tuomi, Tiinamaija" sort="Tuomi, Tiinamaija" uniqKey="Tuomi T" first="Tiinamaija" last="Tuomi">Tiinamaija Tuomi</name></country><country name="États-Unis"><region name="Caroline du Nord"><name sortKey="Cobb, Jeff" sort="Cobb, Jeff" uniqKey="Cobb J" first="Jeff" last="Cobb">Jeff Cobb</name></region></country><country name="France"><region name="Hauts-de-France"><name sortKey="Yengo, Loic" sort="Yengo, Loic" uniqKey="Yengo L" first="Loic" last="Yengo">Loic Yengo</name></region><name sortKey="Balkau, Beverley" sort="Balkau, Beverley" uniqKey="Balkau B" first="Beverley" last="Balkau">Beverley Balkau</name><name sortKey="Froguel, Philippe" sort="Froguel, Philippe" uniqKey="Froguel P" first="Philippe" last="Froguel">Philippe Froguel</name></country><country name="Suède"><noRegion><name sortKey="Kravi, Jasmina" sort="Kravi, Jasmina" uniqKey="Kravi J" first="Jasmina" last="Kravi">Jasmina Kravi</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D77 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000D77 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:28597074
|texte= Early metabolic markers identify potential targets for the prevention of type 2 diabetes.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:28597074" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |